CClinicalTrials.gg
Sign In
TerminatedNCT03287817ALEXANDERUpdated Jul 14, 2025Results posted

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

A Phase 1/2 interventional study of AUTO3 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Autolus Limited. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Autolus Limited · Phase 1/2, Interventional, and Treatment

Why this study was terminated
After reviewing the data and taking into consideration the available treatment landscape in r/r DLBCL, Autolus didn't progress into the Phase II part of the study and submitted a Notification of End of Trial (MHRA reference 46113/0003/001-0016).
Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL

Read the detailed description

The study will consist of 2 phases, a Phase I or dose escalation and expansion phase, and a Phase II. Patients with relapsed or refractory DLBCL will be enrolled in both phases of the study. Eligible patients will undergo leukapheresis in order to harvest T cells, which is the starting material for the manufacture of the autologous CAR T product AUTO3, a CD19 and CD22 dual targeting CAR T cell product. Following pre-conditioning by a chemotherapeutic regimen, the patient will receive AUTO 3 intravenously as a single dose and in addition a limited duration of treatment with an anti-PD1 antibody (either as part of the pre-conditioning regimen or consolidation). Patients will then enter a 36-month follow-up period.

02

Conditions studied

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Keywords

  • Diffuse Large B Cell Lymphoma
  • Relapsed Diffuse Large B Cell Lymphoma
  • Refractory Diffuse Large B Cell Lymphoma
  • AUTO3
  • PD-1
  • Anti PD-1 antibody
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female, aged ≥18 years.
  2. Willing and able to give written, informed consent.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1.

  4. Histologically confirmed DLBCL and large B cell lymphoma subsets, including:

    Phase I and Phase II Cohort 1:

    1. DLBCL, not otherwise specified (NOS), per World Health Organisation classification and DLBCL with MYC oncogene (MYC) and B cell lymphoma 2 (BCL2) gene and/or B cell lymphoma 6 (BCL6) gene rearrangements (double/triple hit).
    2. Transformed DLBCL from follicular lymphoma (FL).
    3. High-grade B cell lymphoma with MYC expression (excluding Burkitt's lymphoma) Phase I and Phase II Cohort 2.
    4. Transformed DLBCL from other indolent lymphomas (excluding Richter's transformation).
    5. Primary mediastinal large B cell lymphoma.

  5. Chemotherapy-refractory disease, defined as one or more of the following:

    1. Stable disease (≤12 months) or progressive disease as best response to most recent chemotherapy containing regimen. Refractory disease after frontline chemo-immunotherapy is allowed.
    2. Disease progression or recurrence in ≤12 months of prior autologous haematopoietic stem cell transplantation (ASCT).

    OR

  6. Relapse after ≥two lines of therapy or after ASCT. At a minimum:

    1. Patients must have received rituximab or another anti-cluster of differentiation antigen 20 (CD20) monoclonal antibody (unless Investigator determines that tumour is CD20-negative) and an anthracycline-containing chemotherapy regimen.
    2. Patients must have either failed ASCT, or be ineligible for or not consenting to ASCT.
    3. Patients with transformed DLBCL must have received at least one line of therapy after transformation to DLBCL.
  7. Positron emission tomography-positive disease per Lugano classification.

  8. For females of childbearing potential, a negative serum or urine pregnancy test must be documented at screening, prior to pre-conditioning and confirmed before receiving the first dose of study treatment.

    For females who are not postmenopausal or surgically sterile, highly effective methods of contraception must be used during the treatment period and for at least 12 months after the last dose of study treatment.

  9. For males, it must be agreed that that two acceptable methods of contraception are used.

  10. Adequate renal, hepatic, pulmonary, and cardiac function defined as:

    1. Creatinine clearance ≥40 cc/min.
    2. Serum alanine aminotransferase / aspartate aminotransferase ≤2.5 x upper limit of normal (ULN).
    3. Total bilirubin ≤1.5 x ULN, except in subjects with Gilbert's syndrome.
    4. Left ventricular ejection fraction (LVEF) ≥50% (by echocardiogram [ECHO] or Multiple gated acquisition scan [MUGA]) unless the institutional lower limit of normal is lower.
    5. Baseline oxygen saturation >92% on room air and ≤Grade 1 dyspnoea.

  11. Patient has adequate bone marrow (BM) function without requiring ongoing blood product or granulocyte-colony stimulating factor support and meets the following criteria:

    1. Absolute neutrophil count ≥1.0 × 10\^9/L.
    2. Absolute lymphocyte count ≥0.3 × 10\^9/L (at enrolment and prior to leukapheresis).
    3. Haemoglobin ≥80 g/L.
    4. Platelets ≥75 × 10\^9/L
  12. No contra-indications for leukapheresis.

Exclusion criteria

Exclusion Criteria:

  1. Prior allogeneic haematopoietic stem cell transplant.
  2. Females who are pregnant or lactating.
  3. History or presence of clinically relevant CNS pathology such as epilepsy, paresis, aphasia, stroke within prior 3 months, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, or psychosis.
  4. Patients with active CNS involvement by malignancy. Patients with history of central nervous system (CNS) involvement with malignancy may be eligible if CNS disease has been effectively treated and provided treatment was at least 4 weeks prior to enrolment (at least 8 weeks prior to AUTO3 infusion).

  5. Clinically significant, uncontrolled heart disease or a recent (within 12 months) cardiac event.

    1. Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded).
    2. Evidence of pericardial effusion
  6. Patients with a history (within 3 months) or evidence of deep vein thrombosis or pulmonary embolism requiring ongoing therapeutic anticoagulation at the time of pre-conditioning.
  7. Patients with active gastrointestinal bleeding.
  8. Patients with any major surgical intervention in the last 3 months.
  9. Active bacterial, viral or fungal infection requiring systemic treatment. Active or latent hepatitis B infection or hepatitis C infection. Testing positive for human immunodeficiency virus, human T cell lymphotropic virus (HTLV1 and 2) or syphilis.
  10. History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 24 months.
  11. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the CNS.
  12. Evidence of active pneumonitis on chest computed tomography (CT) scan at screening or history of drug-induced pneumonitis, idiopathic pulmonary fibrosis, organising pneumonia, or idiopathic pneumonitis.
  13. History of other malignant neoplasms unless disease free for at least 24 months (carcinoma in situ, non-melanoma skin cancer, breast or prostate cancer on hormonal therapy allowed).
  14. Prior treatment with PD1, programmed cell death ligand 1 (PD-L1), or cytotoxic T lymphocyte-associated protein-4-targeted therapy, or tumour necrosis factor (TNF) receptor superfamily agonists within 6 weeks prior to AUTO3 infusion.
  15. Prior treatment with investigational or approved gene therapy or cell therapy products until a dose level has treated at least three patients and has been declared safe.
  16. Prior CD19 or CD22 targeted therapy.

  17. The following medications are excluded:

    1. Steroids: Therapeutic doses of corticosteroids within 7 days of leukapheresis or 72 hours prior to AUTO3 administration. However, physiological replacement, topical, and inhaled steroids are permitted.
    2. Immunosuppression: Immunosuppressive medication must be stopped ≥2 weeks prior to leukapheresis or AUTO3 infusion.
    3. Cytotoxic chemotherapies within 2 weeks of AUTO3 infusion and 1 week prior to leukapheresis (2 weeks for lymphodepleting chemotherapy).
    4. Antibody therapy use including anti-CD20 therapy within 2 weeks prior to AUTO3 infusion, or 5 half-lives of the respective antibody, whichever is shorter.
    5. Granulocyte-colony stimulating factor less than 10 days prior to leukapheresis.
    6. Live vaccine ≤4 weeks prior to enrolment.
    7. Prophylactic intrathecal therapy: Methotrexate within 4 weeks and other intrathecal chemotherapy (e.g. Ara-C) within 2 weeks prior to starting pre-conditioning chemotherapy.
  18. Prior limited radiation therapy within 4 weeks of AUTO3 infusion or within 24 weeks for definitive radiation to chest.
  19. Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.
  20. Known allergy to albumin, dimethyl sulphoxide (DMSO), cyclophosphamide or fludarabine, pembrolizumab or tocilizumab.
  21. Any contraindications to receive anti-PD1 antibody pembrolizumab will be excluded from cohorts requiring administration of pembrolizumab.
  22. Patients, who in the opinion of the Investigator, may not be able to understand or comply with the safety monitoring requirements of the study.

  23. Any other condition that in the Investigator's opinion would make the patient unsuitable for the clinical trial.

    Phase I outpatient cohort:

  24. Subjects who do not have caregiver support (in line with institutional outpatient transplant guidelines) for outpatient/ambulatory care setting.
  25. Subjects who are staying greater than 60 minutes (or whatever is permissible per institutional outpatient transplant guidelines) from the clinical trial site at the time of treatment.

For AUTO3 Infusion: Patients meeting any of the following exclusion criteria must not be treated with AUTO3 or have treatment delayed until they no longer meet these criteria:

  1. Severe intercurrent infection.
  2. Requirement for supplementary oxygen or active pulmonary infiltrates.
  3. Clinical deterioration of organ function (renal and hepatic) exceeding the criteria set at study entry.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    AUTO3

    Patient with relapsed or refractory DLBCL

    Biological: AUTO3

Interventions

  • BiologicalAUTO3

    Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells with limited duration of anti-PD1 antibody (pembrolizumab).

05

What researchers measure

Primary outcomes

  1. Phase I Escalation - Safety (Number of Participants With Grade 3-5 Toxicities) and Identification of Recommended Phase II Dose and Schedule (RP2D).

    Number of patients with Grade 3-5 toxicities during escalation part of Phase I (Cohorts: 50x10\^6 CD19/22 CAR+ T Cells; 50x10\^6 CD19/22 CAR+ T Cells+Pembrolizumab \[Pem\] Day 14; 150-450x10\^6 CD19/22 CAR+ T Cells+Pem Day 14; 150-450x10\^6 CD19/22 CAR+ T Cells+Pem Day -1 in Inpatient Setting) Dose-limiting toxicity defined as: * New non-hematological AE Grade \>=3 using NCI CTCAE (5.0), probably/definitely related to AUTO3, occurring in DLT evaluation period, which did not resolve to Grade 2 or better in 14 days, despite supportive measures. * Grade 4 CRS, neurotoxicity (NT), or cerebral edema, or Grade 3 NT that lasted \>72 hrs * Grade \>3 Disseminated Intravascular Coagulation * Grade \>2 Infusion Reaction with AUTO3 * Grade 4 or 5 event not managed with conventional supportive measures or necessitating dose reduction or modification to trial therapy * Any event that in opinion of Investigator and/or medical monitor put patient at undue risk could also have been considered DLT

    Time frame: Within 75 days of AUTO3 infusion

  2. Phase I Expansion - Safety (Incidence of Grade 3-5 Toxicities) in the Outpatient / Ambulatory Care Setting

    The incidence of Grade 3-5 toxicities during the expansion part of Phase I (Dose cohort: 150 to 450 x 10\^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting)

    Time frame: Within 75 days of AUTO3 infusion

  3. Phase II - Overall Response Rate as Per Lugano Criteria

    This was not analysed due to study termination prior to initiation of Phase II. End of study notification submitted to Medicines and Healthcare products Regulatory Agency (MHRA) (reference 46113/0003/001-0016) - The Last patient last visit was 19 October 2023 (at end of Phase 1) and the study is considered completed (End of study). As per protocol v10.0, end of study is defined as 36 months after the last patient has received AUTO3 infusion or earlier in the event of death or consent withdrawal. Fifty-two patients received AUTO3 in the Phase I part of the study. After reviewing the data and taking into consideration the available treatment landscape in r/r DLBCL, Autolus didn't progress AUTO3-DB1 into the Phase II part of the study. Autolus notified MHRA on 08 November 2021 about enrolment to Phase II of the study (Autolus has decided not to progress AUTO3-DB1 into the Phase II part of the study), and MHRA acknowledged it on 09 November 2021.

    Time frame: Up to 2 years

Secondary outcomes

  1. Feasibility of Generating AUTO3: Number of Patients' Cells Successfully Manufactured as a Proportion of the Number of Patients Undergoing Leukapheresis.

    Feasibility of product generation was examined by assessing the number of AUTO3 successfully manufactured as a fraction of the number of patients undergoing leukapheresis (all patients enrolled).

    Time frame: Up to 8 weeks post leukapheresis.

  2. Determine the Complete Response Rate Following Treatment With AUTO3, as Per Lugano Criteria.

    Participants achieving objective response per Lugano criteria based on independent central radiology review. The Lugano classification of response by 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) PET-CT: 1. no uptake or no residual uptake (when used interim) 2. slight uptake, but below blood pool (mediastinum) 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation) Non-progressive disease * complete metabolic response - score of 1, 2 or 3 in nodal or extranodal sites with or without a residual mass * partial metabolic response - score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size * stable disease or no metabolic response - score of 4 or 5 with no obvious change in FDG uptake Progressive disease score 4 or 5 in any lesion with an increase in intensity of FDG uptake from baseline (and/or

    Time frame: Up to 2 years

  3. Duration of Response (DOR).

    Duration of response was defined as the time from the first observed complete response or partial response \[from the first post-baseline response assessment\] until the date of first progressive disease or death due to underlying cancer (primary reason for death=progressive disease), whichever occurred first. Only responders (patients with complete response \[CR\] or partial response \[PR\]) were included in the analysis of duration of response. Response defined by Lugano classification (see Outcome Measure 5). Patients with death not due to underling cancer (primary reason for death=adverse event \[AE\] or Other or Unknown) or who received new anti-cancer therapy other than SCT or discontinued from the study for other reason than progressive disease (PD) or who were lost to follow-up or reached the time point of analysis without a known record of progression or death had the duration of response censored at the date of last adequate disease assessment for response.

    Time frame: Up to 2 years

  4. Progression-free Survival (PFS).

    The progression-free survival was defined as the time from first AUTO3 treatment until the first progression of disease or death from any cause, whichever occurred first. Patients who reached the time point of analysis without a known record of progression had the PFS censored at the date of last adequate disease assessment. Patients who received a new stem cell transplantation (SCT) were censored at the start date of this new SCT. Patients who received a new anti-cancer therapy or discontinued from the study for other reason than disease progression and who were lost to follow-up were censored at the date of last adequate disease assessment. Response defined by Lugano classification (see Outcome Measure 5).

    Time frame: Up to 2 years

  5. Overall Survival (OS).

    Overall survival (OS) was defined as the time from the date of first AUTO3 treatment up to the date of death, regardless of cause of death. Patients alive at the time of the analysis had the OS censored at the date of last assessment when the patient was known alive.

    Time frame: Up to 2 years

Other outcomes

  1. To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Maximum Concentration)

    Analysis of cells in peripheral blood by polymerase chain reaction and/or flow cytometry at a range of time points in the peripheral blood.

    Time frame: Up to 2 years

  2. To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Area Under the Curve From Day 0 to Day 28)

    Analysis of cells in peripheral blood by polymerase chain reaction and/or flow cytometry at a range of time points in the peripheral blood.

    Time frame: Up to 2 years

  3. To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Time to Maximum Concentration)

    Analysis of cells in peripheral blood by polymerase chain reaction and/or flow cytometry at a range of time points in the peripheral blood.

    Time frame: Up to 2 years

06

Results

Posted Jul 14, 2025
Limitations and caveats
Only results of Phase I of the study are presented due to study termination prior to initiation of Phase II.

Participant flow

Participant flow — Overall Study
Milestone50 x 10^6 Cluster of Differentiation Antigen 19/22 (CD19/CD22) CAR+ T Cells50 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Started4381720
Completed01334
Not completed4251416
Withdrew: Progressive disease423108
Withdrew: Death00234
Withdrew: Physician decision00010
Withdrew: Withdrawal by subject00004

Outcome measures

PrimaryPhase I Escalation - Safety (Number of Participants With Grade 3-5 Toxicities) and Identification of Recommended Phase II Dose and Schedule (RP2D).

Number of patients with Grade 3-5 toxicities during escalation part of Phase I (Cohorts: 50x10\^6 CD19/22 CAR+ T Cells; 50x10\^6 CD19/22 CAR+ T Cells+Pembrolizumab \[Pem\] Day 14; 150-450x10\^6 CD19/22 CAR+ T Cells+Pem Day 14; 150-450x10\^6 CD19/22 CAR+ T Cells+Pem Day -1 in Inpatient Setting) Dose-limiting toxicity defined as: * New non-hematological AE Grade \>=3 using NCI CTCAE (5.0), probably/definitely related to AUTO3, occurring in DLT evaluation period, which did not resolve to Grade 2 or better in 14 days, despite supportive measures. * Grade 4 CRS, neurotoxicity (NT), or cerebral edema, or Grade 3 NT that lasted \>72 hrs * Grade \>3 Disseminated Intravascular Coagulation * Grade \>2 Infusion Reaction with AUTO3 * Grade 4 or 5 event not managed with conventional supportive measures or necessitating dose reduction or modification to trial therapy * Any event that in opinion of Investigator and/or medical monitor put patient at undue risk could also have been considered DLT

Time frame:
Within 75 days of AUTO3 infusion
Reported as:
Number · participants
Phase I Escalation - Safety (Number of Participants With Grade 3-5 Toxicities) and Identification of Recommended Phase II Dose and Schedule (RP2D).
participants50 x 10^6 CD19/CD22 CAR+ T Cells50 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Patients with Grade 3-5 toxicity43713—
Patients with dose-limiting toxicity0000—
PrimaryPhase I Expansion - Safety (Incidence of Grade 3-5 Toxicities) in the Outpatient / Ambulatory Care Setting

The incidence of Grade 3-5 toxicities during the expansion part of Phase I (Dose cohort: 150 to 450 x 10\^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting)

Time frame:
Within 75 days of AUTO3 infusion
Reported as:
Count of participants · Participants
Phase I Expansion - Safety (Incidence of Grade 3-5 Toxicities) in the Outpatient / Ambulatory Care Setting
Participants50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Phase I Expansion - Safety (Incidence of Grade 3-5 Toxicities) in the Outpatient / Ambulatory Care Setting000013
PrimaryPhase II - Overall Response Rate as Per Lugano Criteria

This was not analysed due to study termination prior to initiation of Phase II. End of study notification submitted to Medicines and Healthcare products Regulatory Agency (MHRA) (reference 46113/0003/001-0016) - The Last patient last visit was 19 October 2023 (at end of Phase 1) and the study is considered completed (End of study). As per protocol v10.0, end of study is defined as 36 months after the last patient has received AUTO3 infusion or earlier in the event of death or consent withdrawal. Fifty-two patients received AUTO3 in the Phase I part of the study. After reviewing the data and taking into consideration the available treatment landscape in r/r DLBCL, Autolus didn't progress AUTO3-DB1 into the Phase II part of the study. Autolus notified MHRA on 08 November 2021 about enrolment to Phase II of the study (Autolus has decided not to progress AUTO3-DB1 into the Phase II part of the study), and MHRA acknowledged it on 09 November 2021.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryFeasibility of Generating AUTO3: Number of Patients' Cells Successfully Manufactured as a Proportion of the Number of Patients Undergoing Leukapheresis.

Feasibility of product generation was examined by assessing the number of AUTO3 successfully manufactured as a fraction of the number of patients undergoing leukapheresis (all patients enrolled).

Time frame:
Up to 8 weeks post leukapheresis.
Reported as:
Count of participants · Participants
Feasibility of Generating AUTO3: Number of Patients' Cells Successfully Manufactured as a Proportion of the Number of Patients Undergoing Leukapheresis.
ParticipantsAUTO3
Feasibility of Generating AUTO3: Number of Patients' Cells Successfully Manufactured as a Proportion of the Number of Patients Undergoing Leukapheresis.52
SecondaryDetermine the Complete Response Rate Following Treatment With AUTO3, as Per Lugano Criteria.

Participants achieving objective response per Lugano criteria based on independent central radiology review. The Lugano classification of response by 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) PET-CT: 1. no uptake or no residual uptake (when used interim) 2. slight uptake, but below blood pool (mediastinum) 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation) Non-progressive disease * complete metabolic response - score of 1, 2 or 3 in nodal or extranodal sites with or without a residual mass * partial metabolic response - score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size * stable disease or no metabolic response - score of 4 or 5 with no obvious change in FDG uptake Progressive disease score 4 or 5 in any lesion with an increase in intensity of FDG uptake from baseline (and/or

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Determine the Complete Response Rate Following Treatment With AUTO3, as Per Lugano Criteria.
Participants50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Determine the Complete Response Rate Following Treatment With AUTO3, as Per Lugano Criteria.11488
SecondaryDuration of Response (DOR).

Duration of response was defined as the time from the first observed complete response or partial response \[from the first post-baseline response assessment\] until the date of first progressive disease or death due to underlying cancer (primary reason for death=progressive disease), whichever occurred first. Only responders (patients with complete response \[CR\] or partial response \[PR\]) were included in the analysis of duration of response. Response defined by Lugano classification (see Outcome Measure 5). Patients with death not due to underling cancer (primary reason for death=adverse event \[AE\] or Other or Unknown) or who received new anti-cancer therapy other than SCT or discontinued from the study for other reason than progressive disease (PD) or who were lost to follow-up or reached the time point of analysis without a known record of progression or death had the duration of response censored at the date of last adequate disease assessment for response.

Time frame:
Up to 2 years
Reported as:
Median · months
Duration of Response (DOR).
months50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Duration of Response (DOR).6.31 (1.97 to NA)NA (NA to NA)NA (NA to NA)4.96 (1.91 to NA)NA (NA to NA)
SecondaryProgression-free Survival (PFS).

The progression-free survival was defined as the time from first AUTO3 treatment until the first progression of disease or death from any cause, whichever occurred first. Patients who reached the time point of analysis without a known record of progression had the PFS censored at the date of last adequate disease assessment. Patients who received a new stem cell transplantation (SCT) were censored at the start date of this new SCT. Patients who received a new anti-cancer therapy or discontinued from the study for other reason than disease progression and who were lost to follow-up were censored at the date of last adequate disease assessment. Response defined by Lugano classification (see Outcome Measure 5).

Time frame:
Up to 2 years
Reported as:
Median · months
Progression-free Survival (PFS).
months50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Progression-free Survival (PFS).2.14 (0.76 to NA)2.43 (2.40 to NA)5.67 (0.95 to NA)3.22 (1.87 to NA)3.22 (1.94 to 5.88)
SecondaryOverall Survival (OS).

Overall survival (OS) was defined as the time from the date of first AUTO3 treatment up to the date of death, regardless of cause of death. Patients alive at the time of the analysis had the OS censored at the date of last assessment when the patient was known alive.

Time frame:
Up to 2 years
Reported as:
Median · months
Overall Survival (OS).
months50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
Overall Survival (OS).10.04 (0.95 to NA)6.67 (4.93 to NA)5.67 (1.77 to NA)9.17 (3.32 to NA)NA (NA to NA)
Other pre-specifiedTo Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Maximum Concentration)

Analysis of cells in peripheral blood by polymerase chain reaction and/or flow cytometry at a range of time points in the peripheral blood.

Time frame:
Up to 2 years
Reported as:
Geometric mean · copies/microgram DNA
To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Maximum Concentration)
copies/microgram DNA50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Maximum Concentration)7979.7 (155 to 213000)13157.4 (3900 to 47100)5726.1 (1420 to 11600)4121.4 (174 to 416000)3195.6 (241 to 131000)
Other pre-specifiedTo Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Area Under the Curve From Day 0 to Day 28)

Analysis of cells in peripheral blood by polymerase chain reaction and/or flow cytometry at a range of time points in the peripheral blood.

Time frame:
Up to 2 years
Reported as:
Geometric mean · day*copies/microgram DNA
To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Area Under the Curve From Day 0 to Day 28)
day*copies/microgram DNA50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Area Under the Curve From Day 0 to Day 28)41511.0 (912 to 2370000)109945.2 (35600 to 478000)38397.9 (3510 to 135000)37722.7 (948 to 571000)32152.1 (1060 to 1930000)
Other pre-specifiedTo Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Time to Maximum Concentration)

Analysis of cells in peripheral blood by polymerase chain reaction and/or flow cytometry at a range of time points in the peripheral blood.

Time frame:
Up to 2 years
Reported as:
Median · Days
To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Time to Maximum Concentration)
Days50 x 10^6 CD19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient Setting
To Determine the Expansion and Persistence of AUTO3 Following Adoptive Transfer in Different Lymphoma Subtypes (Time to Maximum Concentration)16.4 (12 to 22)13.9 (11 to 14)9.7 (9 to 35)10.0 (7 to 28)13.1 (7 to 58)

Adverse events

Collected over From AUTO3 infusion (Day -7) until end of study/patient withdrawal OR, when patient initiated a new treatment for their disease (approximately 3 years and 5 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50 x 10^6 CD19/CD22 CAR+ T Cells3/4 (75%)2/4 (50%)4/4 (100%)
50 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 142/3 (66.7%)0/3 (0%)3/3 (100%)
150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 145/8 (62.5%)3/8 (37.5%)8/8 (100%)
150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Inpatient Setting11/17 (64.7%)10/17 (58.8%)15/17 (88.2%)
150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Outpatient Setting6/20 (30%)14/20 (70%)19/20 (95%)
Treatment Not Received6/10 (60%)0/10 (0%)1/10 (10%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
Event50 x 10^6 CD19/CD22 CAR+ T Cells50 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTreatment Not Received
PyrexiaGeneral disorders2/40/30/82/173/200/10
AnaemiaBlood and lymphatic system disorders1/40/30/80/170/200/10
Cytokine release syndromeImmune system disorders1/40/31/81/175/200/10
Depressed level of consciousnessNervous system disorders1/40/30/80/170/200/10
Facial paresisNervous system disorders1/40/30/80/170/200/10
HeadacheNervous system disorders1/40/30/80/170/200/10
HemiparesisNervous system disorders1/40/30/80/170/200/10
NystagmusNervous system disorders1/40/30/80/170/200/10
Radiation pneumonitisInjury, poisoning and procedural complications1/40/30/80/170/200/10
Febrile neutropeniaBlood and lymphatic system disorders0/40/31/82/173/200/10
Most frequent other events
Showing 10 of 180
Most frequent other events
Event50 x 10^6 CD19/CD22 CAR+ T Cells50 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR+ T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTreatment Not Received
Neutrophil count decreasedInvestigations4/43/33/83/172/200/10
Platelet count decreasedInvestigations4/43/33/82/174/200/10
AnaemiaBlood and lymphatic system disorders2/42/36/89/178/200/10
ConstipationGastrointestinal disorders2/42/32/85/170/200/10
PyrexiaGeneral disorders1/42/34/81/175/200/10
NeutropeniaBlood and lymphatic system disorders2/40/34/89/175/200/10
Abdominal painGastrointestinal disorders2/41/30/80/171/200/10
Cytokine release syndromeImmune system disorders2/40/33/84/175/200/10
FatigueGeneral disorders1/41/34/82/178/200/10
HeadacheNervous system disorders2/40/30/85/172/200/10

Baseline characteristics

Sixty-two patients were enrolled. Ten patients did not receive AUTO3 infusion, in 6 patients this was due to death, in 3 patients due to progressive disease (without death), and in 1 patient due to failed eligibility, leaving 52 participants.

Age, Categorical
Age, Categorical(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
<=18 years000000
Between 18 and 65 years43771637
>=65 years00110415
Sex: Female, Male
Sex: Female, Male(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
Female23771635
Male20110417
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
Hispanic or Latino000156
Not Hispanic or Latino43816940
Unknown or Not Reported000066
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
American Indian or Alaska Native000000
Asian000101
Native Hawaiian or Other Pacific Islander000000
Black or African American000134
White438151444
More than one race000000
Unknown or Not Reported000033
Eastern Cooperative Oncology Group (ECOG) score
Eastern Cooperative Oncology Group (ECOG) score(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
ECOG = 01179826
ECOG = 132181226
Disease stage
Disease stage(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
Stage II001236
Stage III0223411
Stage IV415121335
Relapsed/Refractory disease
Relapsed/Refractory disease(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
Relapsed00141116
Refractory0126312
Relapsed and Refractory4257624
Extranodal disease present
Extranodal disease present(Participants)50 x 10^6 Cluster of Differentiation (CD) 19/CD22 CAR-positive T Cells50 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day 14150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Inpatient Setting150 to 450 x 10^6 CD19/CD22 CAR-positive T Cells + Pembrolizumab at Day -1 in an Outpatient SettingTotal
No2236720
Yes215111332

7 further baseline measures are reported on the registry.

07

Study locations

11 sites
  • City of Hope Hospital
    Duarte, California 91010, United States
  • Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center/Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
  • Sylvester Comprehensive Cancer Center / University of Miami
    Miami, Florida 33136, United States
  • Siteman Cancer Center / Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • TriStar Centennial Medical Center /Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • St David's South Austin Medical Center /Sarah Cannon Research Institute
    Austin, Texas 78704, United States
  • The Beatson West of Scotland Cancer Centre / Queen Elizabeth University Hospital
    Glasgow, G12 0YN, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, United Kingdom
  • Manchester University NHS Foundation Trust
    Manchester, United Kingdom
  • Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, United Kingdom
08

References and documents

Publications

  • Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. PubMed 36821767 ↗
  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Study documents

  • Study protocol · May 6, 2021
  • Statistical analysis plan · Dec 21, 2023

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03287817
Lead sponsor
Autolus Limited
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
Sep 5, 2017
Primary completion
Oct 19, 2023
Completion
Oct 19, 2023
Results posted
Jul 14, 2025
Last update
Jul 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma, Large B-Cell, Diffuse→

Other studies from this sponsor

Autolus Limited

Start the discussion